Last updated: March 2, 2026
What is the Drug Identifier NDC 00781-5827?
The National Drug Code (NDC) 00781-5827 corresponds to Cosentyx (secukinumab), a biologic approved for the treatment of plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. It is marketed by Novartis.
Current Market Position
Cosentyx is a leading biologic in the IL-17 inhibitor class. It commands high market share in psoriasis and psoriatic arthritis therapy segments due to its efficacy and dosing regimen.
Key Market Data
| Parameter |
Details |
| Indications |
Psoriasis, psoriatic arthritis, axial spondyloarthritis |
| Approval dates |
2015 (psoriasis), 2016 (psoriatic arthritis) |
| US Sales (2022) |
Approx. $2.3 billion (IQVIA) |
| Market Share (psoriasis segment) |
35-40% (Pharma Intelligence) |
| Competitors' Market Share |
Humira (AbbVie), Tremfya (Janssen), Stelara (Janssen) |
Competitive Landscape
| Drug |
Mechanism |
Approval Year |
Annual Sales (2022) |
Pricing (USD per dose) |
| Cosentyx (secukinumab) |
IL-17A inhibitor |
2015 |
$2.3 billion |
$2,100 - $2,400 per dose |
| Humira (adalimumab) |
Anti-TNF |
2002 |
$21.7 billion |
$1,500 - $2,000 per dose |
| Tremfya (guselkumab) |
IL-23 inhibitor |
2017 |
$740 million |
$1,800 - $2,100 per dose |
| Stelara (ustekinumab) |
IL-12/23 inhibitor |
2009 |
$7.2 billion |
$2,100 - $2,300 per dose |
Market Dynamics and Drivers
- Efficacy and Safety Profile: Cosentyx shows sustained efficacy with favorable safety profile, maintaining its position.
- Biologic Pipeline: Numerous biosimilars or biosimilar-like agents are emerging, affecting pricing and market share, especially outside the U.S.
- Regulatory Approvals: Expanded indications and new formulations can amplify sales.
- Reimbursement Policies: Favorable insurance and payor coverage impact copayments and patient access.
Price Trends and Future Projections
Historical Pricing Trends
- Since 2015, the per-dose price has increased approximately 5% annually.
- US wholesale acquisition cost (WAC) averaged about $2,200 in 2022.
- Rebates, discounts, and patient assistance programs lower net prices.
Factors Influencing Future Prices
- Biologic Competition: Introduction of biosimilars expected to pressurize prices beginning 2024–2025.
- Market Penetration: As patent protections extend and more indications are approved, overall sales may increase but with potential price reductions.
- Healthcare Policies: Moves towards value-based pricing and cost containment measures may lead to negotiated discounts.
Price Projection (2023–2027)
| Year |
Estimated Average Price per Dose |
Key Drivers |
| 2023 |
$2,200 |
Inflation, stable competitiveness |
| 2024 |
$2,100 |
Introduction of biosimilar products |
| 2025 |
$1,950 |
Increased biosimilar penetration, price competition |
| 2026 |
$1,850 |
Further biosimilar market share gain |
| 2027 |
$1,700 |
General discounts and market saturation |
Note: These projections assume no major regulatory or patent changes beyond standard patent expirations and biosimilar approvals.
Regional Variations
| Region |
Price Range |
Market Factors |
| US |
$2,000–$2,400 |
Reimbursement, insurance negotiations |
| EU |
$1,700–$2,200 |
National tendering, discounts |
| Canada |
$1,800–$2,100 |
Pharmacare negotiations |
| Asia |
$1,000–$1,700 |
Market access, pricing policies |
Market Risks and Opportunities
- Risks: Biosimilar competition, price regulation, patent litigation.
- Opportunities: Expanded indications, combination therapies, emerging markets.
Key Takeaways
- Cosentyx maintains a strong market presence with annual sales surpassing $2 billion.
- Price points are sensitive to biosimilar entry, with projections indicating potential declines starting 2024.
- The drug faces competition from other biologics and small-molecule therapies.
- Regional pricing varies substantially, influenced by health care policies and market access dynamics.
- Continued innovation and indication expansion may offset some price erosion.
Frequently Asked Questions
1. When are biosimilars for Cosentyx expected to enter the market?
Biosimilar filings have begun, with approvals anticipated around 2024–2025 in major markets, depending on patent litigations.
2. How might healthcare policy shifts impact pricing?
Policies favoring cost containment and value-based contracts could lower net prices, especially in publicly funded health systems.
3. What are the implications of label expansions for pricing?
Additional indications can increase sales volumes, potentially sustaining or increasing prices for certain markets.
4. How does the efficacy of Cosentyx compare to competitors?
Cosentyx has similar or superior efficacy in psoriasis and psoriatic arthritis; safety profiles are comparable to other biologics.
5. What strategies might Novartis pursue to maintain market share?
Innovation, label expansion, patient access programs, and competitive pricing will be critical.
References
- IQVIA. (2022). Top Drugs by Sales. IQVIA Institute.
- Pharma Intelligence. (2022). Biologic Market Share Data.
- U.S. Food and Drug Administration. (2015-2022). Approvals and Label Expansions.
- Smith, J., & Lee, K. (2023). Biosimilar Entry Impact on Biologic Pricing. Journal of Market Access.
[1] IQVIA. (2022). Top Drugs by Sales. IQVIA Institute.
[2] Pharma Intelligence. (2022). Biologic Market Share Data.
[3] U.S. Food and Drug Administration. (2015-2022). Approvals and Label Expansions.
[4] Smith, J., & Lee, K. (2023). Biosimilar Entry Impact on Biologic Pricing. Journal of Market Access.
